RT001 not checked

Biojiva LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.”In the company’s words, NCT03570931 on ClinicalTrials.gov
Tested for
Infantile Neuroaxonal Dystrophy
Main trialPhase 2/3
“The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD).”In the company’s words, NCT03570931 on ClinicalTrials.gov
Other names
di-deuterated linoleic acid ester · Deuterated linoleic acid

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting 9 Aug 2020 A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
Phase 3Completed 23 Aug 2021 A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
Phase 2Completed 28 Jun 2022 RT001 in Amyotrophic Lateral Sclerosis
Phase 2Unknown 30 Jul 2022 RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RT001

Following is part of Solo: you see every change to RT001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in